Personalis (NASDAQ:PSNL) Stock Price Down 3.5% - Should You Sell?

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shares fell 3.5% on Thursday . The stock traded as low as $7.28 and last traded at $7.25. 1,030,780 shares were traded during mid-day trading, a decline of 10% from the average session volume of 1,139,860 shares. The stock had previously closed at $7.51.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PSNL shares. HC Wainwright boosted their price objective on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Guggenheim assumed coverage on Personalis in a research report on Thursday, May 15th. They set a "buy" rating and a $6.00 target price on the stock. Craig Hallum assumed coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price target for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Personalis presently has an average rating of "Buy" and an average target price of $7.67.

Personalis Trading Up 0.6%

The stock has a 50 day simple moving average of $5.36 and a 200-day simple moving average of $4.85. The firm has a market cap of $667.30 million, a PE ratio of -5.86 and a beta of 1.95.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 48.78% and a negative net margin of 98.10%. On average, equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. grew its position in shares of Personalis by 55.7% during the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock valued at $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of Personalis in the first quarter worth about $47,000. Dynamic Technology Lab Private Ltd boosted its stake in Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock valued at $269,000 after buying an additional 33,044 shares during the last quarter. Royal Bank of Canada grew its holdings in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after buying an additional 2,395 shares in the last quarter. Finally, Trexquant Investment LP grew its holdings in Personalis by 455.0% during the 1st quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock valued at $432,000 after buying an additional 100,804 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.